All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsFRED HUTCHINSON CANCER CENTER

FRED HUTCHINSON CANCER CENTER

Projects attributed to FRED HUTCHINSON CANCER CENTER within this analysis sample.

In This Analysis
Projects
3
NIH Funding
$2.1M
Projects(3)
ProjectPICategoryFunding
Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy
R37CA286450
HAFFNER, MICHAEL C (contact)Therapeutics$1.4M
Project 3: Modulating Androgen Receptor Signaling to Enhance the Efficacy of CAR T Cell Therapy for Advanced Prostate Cancer
5P50CA097186-24
LEE, JOHN KYUNGInfrastructure$476K
Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations
R21CA283589
OROZCO, JOHNNIE JOSE (contact)Therapeutics$280K
See FRED HUTCHINSON CANCER CENTER’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.